Getting Prescribed at 65+: Geriatric Considerations Prescribers Weigh

The Sarcopenic Obesity Challenge

Adults over 65 face a clinical challenge younger patients don't: sarcopenic obesity — the combination of excess fat and reduced muscle mass that becomes increasingly common with age. GLP-1 medications cause weight loss, but that weight loss includes both fat and lean tissue. In younger adults, the lean tissue loss is generally manageable. In older adults who already have reduced muscle mass, further lean tissue loss can increase fall risk, reduce functional independence, and worsen frailty.

This doesn't mean GLP-1s are contraindicated in older adults. It means prescribers approach dosing, monitoring, and lifestyle recommendations differently. The emphasis shifts heavily toward protein intake optimization (1.0-1.2 g/kg/day minimum), resistance exercise, and regular assessment of muscle function — grip strength, gait speed, and the ability to rise from a chair without using arms.

Polypharmacy: The Medication Interaction Web

The average adult over 65 takes 5-9 medications. Adding a GLP-1 to this medication portfolio requires careful review because GLP-1s slow gastric emptying, which can affect the absorption timing of other oral medications. Medications with narrow therapeutic windows — warfarin, levothyroxine, certain cardiac medications — need particular attention.

Your prescriber should perform a medication reconciliation before starting GLP-1 therapy. For some medications, timing adjustments are sufficient (taking them at different times of day). For others, dose adjustments or more frequent monitoring may be needed. Your pharmacist is also a key resource here — they can screen for interactions that might not be flagged during a prescriber visit.

The Medicare GLP-1 Bridge: A Game-Changer for 65+

The Medicare GLP-1 Bridge program, which launched July 1, 2026, is particularly transformative for the 65+ population. Before the Bridge, Medicare Part D plans couldn't cover GLP-1s prescribed for weight loss. Many older adults who would have benefited from treatment were priced out at $900-1,300/month.

The Bridge offers eligible beneficiaries Wegovy, Zepbound (KwikPen), and Foundayo at a $50 monthly copay. The program requires BMI ≥ 30 (or ≥ 27 with a comorbidity), Part D enrollment, and prescriber certification that the medication is being used alongside lifestyle modification. The program runs through December 31, 2027.

Finding the Right Prescriber for 65+ GLP-1 Management

Not every prescriber has experience managing GLP-1 therapy in older adults. Look for geriatric medicine specialists, endocrinologists with geriatric experience, or obesity medicine specialists who explicitly serve the 65+ population. The prescriber should have a clear protocol for monitoring muscle mass (DEXA scans or equivalent), nutritional status, and fall risk alongside standard GLP-1 monitoring.

Telehealth platforms can prescribe GLP-1s to older adults, but verify that the intake process accounts for the geriatric-specific considerations — polypharmacy review, sarcopenia screening, and fall risk assessment. A platform that uses the same intake process for a 25-year-old and a 72-year-old is missing important clinical variables.